IP Library › Granted Patent US 10,975,388
Granted Patent B2
US 10,975,388 · App. 15/842,820 · Granted Apr 13, 2021

Methods and compositions for nucleic acid and protein payload delivery

Inventors: Andre Ronald Watson (San Francisco, CA); Christian Foster (Oakland, CA)
Assignee: LIGANDAL, INC.
C12N15/85A61K9/0019A61K9/0085A61K9/5146A61K31/40A61K31/7105A61K47/34A61K47/42A61K47/549A61K47/64A61K47/645A61K47/6455A61K47/6807A61K48/0016A61K48/0041A61K48/0075A61P3/10A61P35/00A61P37/00B82Y5/00C12N15/102C12N15/111C12N15/87C12N9/22C12N2310/14C12N2310/20C12N2310/3517C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,975,388
App. No.
15/842,820
Granted
Apr 13, 2021
Kind
B2
Abstract

Provided are methods and compositions for delivering a nucleic acid, protein, and/or ribonucleoprotein payload to a cell. Also provided are delivery molecules that include a peptide targeting ligand conjugated to a protein or nucleic acid payload (e.g., an siRNA molecule), or conjugated to a charged polymer polypeptide domain (e.g., poly-arginine such as 9R or a poly-histidine such as 6H, and the like). The targeting ligand provides for (i) targeted binding to a cell surface protein, and (ii) engagement of a long endosomal recycling pathway. As such, when the targeting ligand engages the intended cell surface protein, the delivery molecule enters the cell (e.g., via endocytosis) but is preferentially directed away from the lysosomal degradation pathway.

Claims (3)

1. A delivery molecule, comprising a peptide targeting ligand comprising the amino acid sequence MIASQFLSALTLVLLIKESGA (SEQ ID NO:56), the targeting ligand conjugated to a charged polymer polypeptide domain comprising the amino acid sequence RRRRRRRRR (9R) (SEQ ID NO:15), wherein the targeting ligand provides for targeted binding to a cell surface protein, and wherein the charged polymer polypeptide domain is condensed with a payload comprising a ribonucleoprotein complex.

2. The delivery molecule of claim 1 , wherein the targeting ligand comprises a cysteine residue.

3. The delivery molecule of claim 1 , wherein the targeting ligand comprises a cysteine substitution or insertion, at one or more internal amino acid positions, relative to a corresponding wild type amino acid sequence.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2019
From: WATSON, ANDRE RONALD; FOSTER, CHRISTIAN
To: LIGANDAL, INC.
Reel/Frame 048282/0370 →
Continuity (5)
Provisional Application 62434344 · Dec 14, 2016
Provisional Application 62443522 · Jan 6, 2017
Provisional Application 62443567 · Jan 6, 2017
Provisional Application 62517346 · Jun 9, 2017
Related Publication 20180161447A1 · Jun 14, 2018